REG - Hikma Pharmaceutical - Hikma completes Xellia acquisition

Hikma PharmaceuticalsAnnouncement

10/09/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240910:nRSJ5017Da&default-theme=true

RNS Number : 5017D  Hikma Pharmaceuticals Plc  10 September 2024

Hikma completes Xellia acquisition

London, 10 September 2024 - Hikma Pharmaceuticals PLC (Hikma, Group), the
multinational pharmaceutical group, today announces that it has completed its
acquisition of Xellia Pharmaceuticals' US finished dosage form (FDF) business
and related assets following clearance under applicable US antitrust laws.
The acquisition includes a commercial portfolio and pipeline of differentiated
products, a manufacturing facility in Cleveland, Ohio, sales and marketing
capabilities, and an R&D center in Zagreb, Croatia. Hikma has paid cash
consideration of $135 million (subject to customary adjustments), with
additional contingent consideration of up to $50 million payable upon
achievement of certain regulatory and commercial milestones.

 

Transaction highlights:

 * Supports the long-term growth of Hikma's Injectables business

 * Diversifies and enriches Hikma's US injectables portfolio and pipeline

 * Expands Hikma's high-quality manufacturing capacity

 * Adds complex manufacturing technologies

 * Enhances Hikma's R&D capabilities

 * Neutral to Group core earnings in the first 12 months following closing and
accretive thereafter, with meaningful longer-term benefits

 

Dr Bill Larkins, President, Injectables commented:

 

"This acquisition adds significant scale to our US operations and enhances our
US injectable manufacturing capabilities and portfolio by adding complex
technologies. I am confident that this transaction will deliver significant
future value to our Injectables business, supporting growth over the medium
term."

 

 

--  ENDS -

 

Enquiries:

Hikma
(Investors)

 Susan Ringdal                                                                                    +44 (0)20 7399 2760/ +44 (0)7776 477050

 EVP, Strategic Planning and Global Affairs
 Guy Featherstone                                                                                 +44 (0)20 3892 4389/ +44 (0)7795 896738

 Director, Investor Relations
 Layan Kalisse                                                                                    +44 (0)20 7399 2788/ +44 (0)7970 709912

 Senior Associate, Investor Relations

 Press

 Teneo - Doug Campbell / Rob Yates

                                                                                                  +44 (0)7753 136628/ +44 (0)7715 375443
 Hikma - Steve Weiss                                                                              +1-732-788-8279

 

 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY)
(LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P and BBB-/positive Fitch)

 

Hikma helps put better health within reach every day for millions of people
around the world. For more than 45 years, we've been creating high-quality
medicines and making them accessible to the people who need them.
Headquartered in the UK, we are a global company with a local presence across
North America, the Middle East and North Africa (MENA) and Europe, and we use
our unique insight and expertise to transform cutting-edge science into
innovative solutions that transform people's lives. We're committed to our
customers, and the people they care for, and by thinking creatively and acting
practically, we provide them with a broad range of branded and non-branded
generic medicines. Together, our 9,100 colleagues are helping to shape a
healthier world that enriches all our communities. We are a leading licensing
partner, and through our venture capital arm, are helping bring innovative
health technologies to people around the world. For more information, please
visit: www.hikma.com (http://www.hikma.com)

©2024 Hikma Pharmaceuticals PLC. All rights reserved.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  ACQFLFLTALIAIIS